Manikanta.jpg

Mr. Manikanta Sodasani

B.Pharm. 

TCABS-E Scientist,

Program Manager,

Biophysics, 

Department of Intramural Research Core (IRC)

The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam (A.P.) India.

Telephone: +91 8660301662; Email: tcabse.india(at)gmail(dot)com.

Research Interests: Protein liquid-liquid phase separations: Delivery of drugs and pharmaceuticals is always challenging while composing the oral and IV formulations. No matter how specific a given drug can be, the precise delivery to the target is critical to decrease the systemic toxicity. My goal is to take advantage of the protein liquid-liquid phase separations (LLPS) to deliver therapeutic RNA molecules including drugs and pharmaceuticals. We have currently shortlisted a few intrinsically disordered proteins that exhibit LLPS nature and are evaluating them with different formulations for the delivery of RNA therapeutics.

LLPS.png

Publications (Listed Chronologically)

  1. Vissapragada, M., Addala, S., Sodasani, M., Yedidi, R.S. (2021) Major structural deviations in the receptor binding domain of SARS-CoV-2 spike protein may pose threat to the existing vaccines. TCABSE-J, Vol. 1, Issue 1:12-14. Epub: Apr 13th, 2021. (View publication)

  2. Sodasani, M. and Yedidi, R.S. (2021) Leveraging the protein liquid-liquid phase separation droplets as potential drug delivery vehicles. TCABSE-J, Vol. 1, Issue 2:28-30. Epub: Oct 15th , 2021. (View publication)

  3. Addala, S., Vissapragada, M., Aggunna, M., Mukala, N., Lanka, M., Gampa, S., Sodasani, M., Chintalapati, J., Kamidi, A., Veeranna, R.P., Yedidi, R.S. (2022) Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design. Vaccines. 2022; 10(6):841. https://doi.org/10.3390/vaccines10060841

  4. Lanka, M., Sodasani, M. and Yedidi, R.S. (2022). Novel biophysical strategy for the delivery of therapeutic microRNA molecules for Cancer and infectious diseases treatment. TCABSE-J, Vol. 1, Issue 4:9-17. Epub: Oct 5th , 2022. (View publication)

  5. Vissapragada, M., Addala, S., Aggunna, M., Mukala, N., Chintalapati, J., Kamidi, A., Korabu, M. S., Lanka, M., Palla, H., Sodasani, M., Grandhi, A. V. K. S., Unnisa, A., Adhikari, A., Kumpatla, A. D., Yerabolu, B., Paidi, C., Pemmadi, G., Penta, H., Mallavalli, H., Gadigoyala, K., Voleti, M., Ravilisetty, M., Akula, N., Gundubogula, P., Puripanda, P., Lankapalli, P., Sandipamu, P., Nagraj, R., Tamarala, R., Geddam, R., Kolluru, R., Oggu, R., Garbhapu, R., Meka, S., Geddam, S., Viyyapu, S., Sammangi, S., Javvaji, S., Chattopadhyay, S., Inemella, S., Grandhi, V., Chigilipalli, Y., Puppala, Y. C., Sharma, M. H., Gubbala, S., Thakur, K., Aanaparthi, S., Pothula, B. and Yedidi, R.S. (2022). In silico analysis of molnupiravir usage vs. efficacy of COVID-19 vaccines. TCABSE-J, Vol. 1, Issue 5:1-14. Mar 22nd, 2023. Epub: Oct 20th, 2022. (View publication)